MedTrace Logo

Safety and Efficacy of a Single Dose of a Polyphenol-enriched Brown Seaweed Powder in Human

NCT00936754 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2010-01-20

No results posted yet for this study

Summary

The primary endpoint of this trial will be to evaluate the safety of a single administration in human of a dose of 500 mg of a polyphenol-rich algal powder when taken 30 minutes before a test meal. The secondary endpoint of this trial will be to evaluate if a single administration in human of a dose of 500 mg of a polyphenol-rich algal powder is able to reduce the rate of carbohydrate absorption as measured by following postprandial glycemia and insulinemia.

Conditions

  • Glycemic Index

Interventions

DIETARY_SUPPLEMENT

Brown seaweed powder

500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)

DIETARY_SUPPLEMENT

Placebo

Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)

Sponsors & Collaborators

  • innoVactiv Inc.

    lead INDUSTRY

Principal Investigators

  • Patrick Couture, MD, PhD · Institut des nutraceutiques et des aliments fonctionnels

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-11-30
Completion
2010-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00936754 on ClinicalTrials.gov